Oruka Therapeutics
ORKA
12 hedge funds and large institutions have $910K invested in Oruka Therapeutics in 2019 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 12 → 12 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
0.64% less ownership
Funds ownership: 1.61% → 0.97% (-0.64%)
54% less capital invested
Capital invested by funds: $1.96M → $910K (-$1.05M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$120K |
| 2 |
ARTA
A.R.T. Advisors
New York
|
+$85.9K |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
+$1.47K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$147 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Aveo Capital Partners
Englewood,
Colorado
|
-$661K |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$263K |
| 3 |
QT
Quantamental Technologies
White Plains,
New York
|
-$16.8K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$13K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $535K | +$120K | +1,634 | +24% |
|
|
TCM
2
Tekla Capital Management
Boston,
Massachusetts
| $192K | – | – | – |
|
3
Acadian Asset Management
Boston,
Massachusetts
| $93K | – | – | – |
|
|
ARTA
4
A.R.T. Advisors
New York
| $75K | +$85.9K | +1,168 | New |
|
|
QT
5
Quantamental Technologies
White Plains,
New York
| $13K | -$16.8K | -228 | -53% |
|
6
Morgan Stanley
New York
| $1K | – | – | – |
|
|
7
Victory Capital Management
San Antonio,
Texas
| $1K | +$1.47K | +20 | New |
|
|
ACP
8
Aveo Capital Partners
Englewood,
Colorado
| – | -$661K | -7,976 | Closed |
|
|
9
Hudson Bay Capital Management
Stamford,
Connecticut
| – | -$263K | -2,989 | Closed |
|
|
10
UBS Group
Zurich,
Switzerland
| – | -$13K | -151 | Closed |
|
|
11
Fidelity Investments
Boston,
Massachusetts
| – | +$147 | +2 | New |
|
ORKA Hedge Fund Activity: Q3 2019 in Review
12 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q3 2019, worth a combined $910K — down 54% from $1.96M a quarter earlier.
Fund positioning in ORKA was balanced in Q3 2019: 3 funds opened new positions, 3 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $120K. The largest seller was Aveo Capital Partners, exiting entirely with an estimated $661K sold.
- 12 institutional investors held Oruka Therapeutics (ORKA) as of Q3 2019, unchanged from Q2 2019.
- Funds reported $910K of Oruka Therapeutics stock for Q3 2019, down 54% quarter-over-quarter.
- 3 funds opened new Oruka Therapeutics positions in Q3 2019 and 3 closed out, a net change of 0 holders.
- The largest Oruka Therapeutics buyer in Q3 2019 was Renaissance Technologies, an estimated $120K added.
- The largest Oruka Therapeutics seller in Q3 2019 was Aveo Capital Partners, an estimated $661K sold.
Based on aggregated 13F filings for Q3 2019.